JP6905464B2 - 上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異 - Google Patents

上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異 Download PDF

Info

Publication number
JP6905464B2
JP6905464B2 JP2017504814A JP2017504814A JP6905464B2 JP 6905464 B2 JP6905464 B2 JP 6905464B2 JP 2017504814 A JP2017504814 A JP 2017504814A JP 2017504814 A JP2017504814 A JP 2017504814A JP 6905464 B2 JP6905464 B2 JP 6905464B2
Authority
JP
Japan
Prior art keywords
seq
egfr
mutations
amino acid
cetuximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522890A5 (enExample
JP2017522890A (ja
Inventor
バルデッリ，アルベルト
アレーナ，サブリナ
ビラドット，クラーラ モンタグ
ビラドット，クラーラ モンタグ
メストレス，ホアン アルバネイ
メストレス，ホアン アルバネイ
ゲリン，アナ ロヴィーラ
ゲリン，アナ ロヴィーラ
パリシオ，ベアトリス ベッロシッロ
パリシオ，ベアトリス ベッロシッロ
マッセグ，アルバ ダルマサス
マッセグ，アルバ ダルマサス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017522890A publication Critical patent/JP2017522890A/ja
Publication of JP2017522890A5 publication Critical patent/JP2017522890A5/ja
Application granted granted Critical
Publication of JP6905464B2 publication Critical patent/JP6905464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017504814A 2014-07-28 2014-12-30 上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異 Active JP6905464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382288 2014-07-28
EP14382288.0 2014-07-28
PCT/EP2014/079477 WO2016015788A1 (en) 2014-07-28 2014-12-30 Mutations in the extracellular domain iii of epidermal growth factor receptor gene

Publications (3)

Publication Number Publication Date
JP2017522890A JP2017522890A (ja) 2017-08-17
JP2017522890A5 JP2017522890A5 (enExample) 2018-01-18
JP6905464B2 true JP6905464B2 (ja) 2021-07-21

Family

ID=51225482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504814A Active JP6905464B2 (ja) 2014-07-28 2014-12-30 上皮増殖因子受容体遺伝子の細胞外ドメインｉｉｉ内の変異

Country Status (8)

Country Link
US (2) US11015225B2 (enExample)
EP (2) EP3174896B1 (enExample)
JP (1) JP6905464B2 (enExample)
CN (1) CN106573967B (enExample)
BR (1) BR112017001474A2 (enExample)
CA (1) CA2954952C (enExample)
ES (1) ES2693080T3 (enExample)
WO (1) WO2016015788A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982287B2 (en) * 2015-01-06 2021-04-20 The Johns Hopkins University Response to EGFR blockade
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用
CN115947823B (zh) * 2022-09-29 2024-05-03 江汉大学 一种用于筛选结合和/或激活egfr的有毒金属的表达蛋白及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
CN107988363A (zh) * 2004-03-31 2018-05-04 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
WO2012162267A2 (en) * 2011-05-20 2012-11-29 Fluidigm Corporation Nucleic acid encoding reactions
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene

Also Published As

Publication number Publication date
CA2954952C (en) 2023-05-23
US11015225B2 (en) 2021-05-25
BR112017001474A2 (pt) 2018-02-20
EP3174896B1 (en) 2018-08-22
EP3428185A1 (en) 2019-01-16
EP3174896A1 (en) 2017-06-07
JP2017522890A (ja) 2017-08-17
US20170260250A1 (en) 2017-09-14
ES2693080T3 (es) 2018-12-07
WO2016015788A1 (en) 2016-02-04
CN106573967A (zh) 2017-04-19
CN106573967B (zh) 2022-02-18
CA2954952A1 (en) 2016-02-04
US20210262037A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
Calvayrac et al. Molecular biomarkers for lung adenocarcinoma
KR102442275B1 (ko) 암 전이의 예후 및 치료 방법
CN107794302B (zh) 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
KR102226219B1 (ko) 폐암 전이의 진단, 예후 및 치료 방법
ES2426814T3 (es) Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
CA2842270C (en) Mutations in the epidermal growth factor receptor gene
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
US20140134158A1 (en) Kras mutations and resistance to anti-egfr treatment
TW200902553A (en) K-ras mutations and anti-EGFr antibody therapy
KR20160061424A (ko) 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법
CN111565725A (zh) 基于c-maf状态的乳腺癌的治疗性处理
US20210262037A1 (en) Methods of treating cancer based on identifying mutations in the extracellular domain iii of epidermal growth factor receptor gene
CA2819080A1 (en) Agtr1 as a marker for bevacizumab combination therapies
Caban Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients
CA2742512A1 (en) Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
Ulivi et al. PP 39 Multi-determinants analysis of molecular alterations as predictor of resistance to cetuximab in metastatic colorectal cancer
HK40026235A (en) Therapeutic treatment of breast cancer based on c-maf status
HK1252399B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
TW201309806A (zh) Ｖｅｇｆａ基因啟動子中的單一核苷酸多型性及其作為抗－ｖｅｇｆ治療之預測標記的用途
HK1133045A (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201217

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210318

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210625

R150 Certificate of patent or registration of utility model

Ref document number: 6905464

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250